Switch theme
Sign up to access all valuation multiples
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
2019
173
LTM Revenue $20.5M
LTM EBITDA -$145M
-$132M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ITeos Therapeutics has a last 12-month revenue (LTM) of $20.5M and a last 12-month EBITDA of -$145M.
In the most recent fiscal year, ITeos Therapeutics achieved revenue of $35.0M and an EBITDA of -$153M.
ITeos Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ITeos Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $20.5M | XXX | $35.0M | XXX | XXX | XXX |
| Gross Profit | $20.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$145M | XXX | -$153M | XXX | XXX | XXX |
| EBITDA Margin | -705% | XXX | -437% | XXX | XXX | XXX |
| EBIT | -$152M | XXX | -$154M | XXX | XXX | XXX |
| EBIT Margin | -742% | XXX | -441% | XXX | XXX | XXX |
| Net Profit | -$130M | XXX | -$134M | XXX | XXX | XXX |
| Net Margin | -634% | XXX | -384% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ITeos Therapeutics's stock price is $10.
ITeos Therapeutics has current market cap of $384M, and EV of -$132M.
See ITeos Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$132M | $384M | XXX | XXX | XXX | XXX | $-3.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ITeos Therapeutics has market cap of $384M and EV of -$132M.
ITeos Therapeutics's trades at -3.8x EV/Revenue multiple, and 0.9x EV/EBITDA.
Equity research analysts estimate ITeos Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ITeos Therapeutics has a P/E ratio of -3.0x.
See valuation multiples for ITeos Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $384M | XXX | $384M | XXX | XXX | XXX |
| EV (current) | -$132M | XXX | -$132M | XXX | XXX | XXX |
| EV/Revenue | -6.4x | XXX | -3.8x | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/Gross Profit | -6.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -2.9x | XXX | XXX | XXX |
| EV/FCF | 1.5x | XXX | 1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialITeos Therapeutics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.1M for the same period.
ITeos Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ITeos Therapeutics's rule of X is -705% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ITeos Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -705% | XXX | -437% | XXX | XXX | XXX |
| EBITDA Growth | -23% | XXX | -8% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -705% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 416% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 541% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ITeos Therapeutics acquired XXX companies to date.
Last acquisition by ITeos Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . ITeos Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ITeos Therapeutics founded? | ITeos Therapeutics was founded in 2019. |
| Where is ITeos Therapeutics headquartered? | ITeos Therapeutics is headquartered in United States of America. |
| How many employees does ITeos Therapeutics have? | As of today, ITeos Therapeutics has 173 employees. |
| Who is the CEO of ITeos Therapeutics? | ITeos Therapeutics's CEO is Dr. Michel Detheux, PhD. |
| Is ITeos Therapeutics publicy listed? | Yes, ITeos Therapeutics is a public company listed on NAS. |
| What is the stock symbol of ITeos Therapeutics? | ITeos Therapeutics trades under ITOS ticker. |
| When did ITeos Therapeutics go public? | ITeos Therapeutics went public in 2020. |
| Who are competitors of ITeos Therapeutics? | Similar companies to ITeos Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ITeos Therapeutics? | ITeos Therapeutics's current market cap is $384M |
| What is the current revenue of ITeos Therapeutics? | ITeos Therapeutics's last 12 months revenue is $20.5M. |
| What is the current EV/Revenue multiple of ITeos Therapeutics? | Current revenue multiple of ITeos Therapeutics is -6.4x. |
| Is ITeos Therapeutics profitable? | Yes, ITeos Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ITeos Therapeutics? | ITeos Therapeutics's last 12 months EBITDA is -$145M. |
| What is ITeos Therapeutics's EBITDA margin? | ITeos Therapeutics's last 12 months EBITDA margin is -705%. |
| What is the current EV/EBITDA multiple of ITeos Therapeutics? | Current EBITDA multiple of ITeos Therapeutics is 0.9x. |
| What is the current FCF of ITeos Therapeutics? | ITeos Therapeutics's last 12 months FCF is -$88.1M. |
| What is ITeos Therapeutics's FCF margin? | ITeos Therapeutics's last 12 months FCF margin is -429%. |
| What is the current EV/FCF multiple of ITeos Therapeutics? | Current FCF multiple of ITeos Therapeutics is 1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
